Encorafenib

About

Therapy type: Targeted therapy

Therapy strategy: B-RAF inhibition

Mappings

NCI Thesaurus: Encorafenib (ncit:C98283)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRAF p.V600E Melanoma Binimetinib, Encorafenib FDA
Sensitivity (+) BRAF p.V600K Melanoma Binimetinib, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Melanoma Binimetinib, Encorafenib FDA
Sensitivity (+) BRAF p.V600K Melanoma Binimetinib, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Non-Small Cell Lung Cancer Binimetinib, Encorafenib FDA
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin FDA
Sensitivity (+) BRAF p.V600E Melanoma Binimetinib, Encorafenib HC
Sensitivity (+) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib HC
Sensitivity (+) BRAF p.V600E Melanoma Binimetinib, Encorafenib HC
Sensitivity (+) BRAF p.V600K Melanoma Binimetinib, Encorafenib HC